Another clinical trial was also carried out by researchers from Compass Pathways. With 233 participants in over 20 locations across Europe, this trial is believed to be the largest clinical trial regarding magic mushrooms and depression. The goal of this trial was to determine the perfect dosage for treatment-resistant depression. At the start of the trial, the participants were randomly separated into three groups. Each group was administered 1mg, 10mg, and 25mg dosage of psilocybin. Three weeks after the start of the trial, results showed that over 28% of 25 mg patients were in remission, as to 8% and 9% of the 1mg and 10mg, respectively.
Magic mushrooms are the safest means of battling depression and other forms of mental illness. However, it’s advisable to take it in a secure environment under the guidance of experienced professionals.
